Genetic Changes In River Blindness Leading To Resistance To Drug Treatment

Main Category: Tropical Diseases
Also Included In: MRSA / Drug Resistance;  Lymphology/Lymphedema
Article Date: 02 Sep 2007 - 5:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Ivermectin, the standard drug for treating river blindness (onchocerciasis), is causing genetic changes in the parasite that causes the disease, according to a new study by Roger Prichard (McGill University, Canada) and colleagues, published in the open-access journal PLoS Neglected Tropical Diseases. These genetic changes have previously been linked with parasites becoming resistant to ivermectin.

The study is being published as a "sneak preview" research article ahead of the official launch of PLoS Neglected Tropical Diseases later this year.

Recent reports of patients failing to respond to ivermectin treatment have suggested the emergence of drug-resistant Onchocerca volvulus (the parasite that causes river blindness), and recent studies have associated ivermectin resistance with certain genetic markers, particularly the â-tubulin gene. In Prichard and colleagues' study, genetic changes in â-tubulin were seen in parasites obtained from patients exposed to repeated ivermectin treatment when compared with parasites obtained from the same patients before any exposure to ivermectin. Furthermore, the researchers found that the extent of the genetic changes was dependent on the level of ivermectin treatment exposure.

Ivermectin has been used for mass treatment of river blindness for up to 18 years and is currently the only safe drug available for mass treatment of the estimated 37 million people infected with the O. volvulus parasite. According to this study, the genetic selection shown "could have implications for the development of ivermectin resistance in O. volvulus and for the ongoing onchocerciasis control programmes."

In a related commentary article, publishing in PLoS Neglected Tropical Diseases, Sara Lustigman (New York Blood Center) and James McCarter (Washington University School of Medicine), who were not involved in Prichard and colleagues' study, say that the study is "a wake-up call for onchocerciasis control programs to select their treatment regimens carefully and to develop plans for detecting ivermectin resistance and the associated genetic markers."

----------------------------
Article adapted by Medical News Today from original press release.
----------------------------

These two articles are the first to be released by PLoS Neglected Tropical Diseases, the Public Library of Science's newest journal. The journal will be the first publication devoted entirely to neglected tropical diseases such as elephantiasis, Chagas disease, leprosy, hookworm, schistosomiasis, and African sleeping sickness. All papers published in PLoS Neglected Tropical Diseases will be freely available online, and published under a license that allows readers to freely distribute and translate them and create derivative works.

Click here for link to published article.

Citations:
Bourguinat C, Pion SDS, Kamgno J, Gardon J, Duke BOL, et al (2007) Genetic Selection of Low Fertile Onchocerca volvulus by Ivermectin Treatment. PLoS Negl Trop Dis 1(1): e72. doi:10.1371/journal.pntd.0000072 Lustigman S, McCarter JP (2007) Ivermectin Resistance in Onchocerca volvulus: Toward a Genetic Basis. PLoS Negl Trop Dis 1(1): e76. doi:10.1371/journal.pntd.0000076

Contact:
Roger K. Prichard
McGill University
Institute of Parasitology
21111 Lakeshore Road
Ste-Anne-de-Bellevue, Quebec H9X3V9

PLoS Neglected Tropical Diseases (http://www.plosntds.org/) is an open-access, peer-reviewed journal published weekly by the Public Library of Science (PLoS).

Source: Johanna Dehlinger
Public Library of Science